Pages that link to "Q59607930"
Jump to navigation
Jump to search
The following pages link to Inhibition of Atherosclerosis Development in Cholesterol-Fed Human Apolipoprotein A-I–Transgenic Rabbits (Q59607930):
Displaying 50 items.
- Gene therapy for lipid disorders (Q24792755) (← links)
- Antioxidant properties of HDL (Q26777244) (← links)
- Rabbit models for the study of human atherosclerosis: from pathophysiological mechanisms to translational medicine (Q26853133) (← links)
- Cardioprotective functions of HDLs (Q27000421) (← links)
- New Era of Lipid-Lowering Drugs (Q28072298) (← links)
- Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I (Q28366335) (← links)
- Dietary oil modifies the plasma proteome during aging in the rat (Q28569420) (← links)
- Delayed loss of cholesterol from a localized lipoprotein depot in apolipoprotein A-I-deficient mice (Q28587419) (← links)
- Atheroprotective mechanisms of HDL. (Q33688098) (← links)
- Trans-splicing into highly abundant albumin transcripts for production of therapeutic proteins in vivo (Q33713295) (← links)
- Somatic gene therapy for dyslipidemias (Q33731030) (← links)
- High-density lipoprotein subclasses and apolipoprotein A-I. (Q33746632) (← links)
- High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences (Q33817228) (← links)
- Animal models for atherosclerosis, restenosis, and endovascular graft research (Q33849706) (← links)
- The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? (Q33993233) (← links)
- Gene therapy for dyslipidemia: clinical prospects (Q34107177) (← links)
- Postprandial lipemia and coronary risk (Q34107425) (← links)
- High-density lipoprotein metabolism: molecular targets for new therapies for atherosclerosis (Q34107511) (← links)
- CETP inhibitors and cardiovascular disease: Time to think again (Q34109100) (← links)
- Structural models of human apolipoprotein A-I: a critical analysis and review (Q34201689) (← links)
- Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. (Q34225057) (← links)
- Advances in experimental dyslipidemia and atherosclerosis (Q34368686) (← links)
- Recent advances in liver-directed gene therapy for dyslipidemia (Q34586826) (← links)
- High-density lipoproteins and atherosclerosis (Q34990624) (← links)
- HDL in risk prediction and its direct and indirect involvement in atherogenesis (Q35062386) (← links)
- HDL therapy for the acute treatment of atherosclerosis (Q35062398) (← links)
- Polymorphisms of mouse apolipoprotein A-II alter its physical and functional nature (Q35092902) (← links)
- Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA (Q35120961) (← links)
- High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions (Q35152178) (← links)
- Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment (Q35203793) (← links)
- Transgenic rabbits as therapeutic protein bioreactors and human disease models (Q35209836) (← links)
- Regulation of reverse cholesterol transport and clinical implications (Q35212558) (← links)
- The transgenic rabbit as model for human diseases and as a source of biologically active recombinant proteins. (Q35577270) (← links)
- Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-I kinetics in postmenopausal women (Q35590308) (← links)
- HDL and CER-001 Inverse-Dose Dependent Inhibition of Atherosclerotic Plaque Formation in apoE-/- Mice: Evidence of ABCA1 Down-Regulation (Q35763571) (← links)
- Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent (Q35793779) (← links)
- HDL as a target in the treatment of atherosclerotic cardiovascular disease (Q36058450) (← links)
- Therapeutic approaches to raising plasma HDL-cholesterol levels (Q36304186) (← links)
- Reducing protein oxidation in low-flow electrospray enables deeper investigation of proteoforms by top down proteomics (Q36439822) (← links)
- The rationale for using apoA-I as a clinical marker of cardiovascular risk (Q36455889) (← links)
- Transgenic rabbit models for studying human cardiovascular diseases (Q36481289) (← links)
- High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease (Q36766976) (← links)
- Adenoviral expression of human lecithin-cholesterol acyltransferase in nonhuman primates leads to an antiatherogenic lipoprotein phenotype by increasing high-density lipoprotein and lowering low-density lipoprotein (Q36989495) (← links)
- Regulation of bile acid and cholesterol metabolism by PPARs (Q37266779) (← links)
- Omega-3 fatty acids regulate gene expression levels differently in subjects carrying the PPARalpha L162V polymorphism. (Q37350799) (← links)
- ApoA-I induced CD31 in bone marrow-derived vascular progenitor cells increases adhesion: implications for vascular repair. (Q37364728) (← links)
- Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection (Q37713673) (← links)
- Animal models for the atherosclerosis research: a review (Q37862141) (← links)
- ApoA-I mimetics (Q38293513) (← links)
- Targeting high-density lipoproteins: increasing de novo production versus decreasing clearance (Q38431166) (← links)